BCL2L1 and melanoma: The use of a panel of melanoma cell lines showing variable expression level of endogenous BCL-XL protein corroborated the observations made in the engineered cell lines indicating clinical and pathophysiological relevance to cancer that express a high level of BCL-XL, including melanoma.